Eli Lilly is buying Versanis to expand its portfolio of obesity drugs

Key things Eli Lilly has agreed to buy privately held biopharmaceutical company Versanis for up to $1.93 billion. The purchase is aimed at strengthening Lilly’s reach in the anti-obesity drug market. Lilly said last month that its experimental obesity drug had been very successful in helping patients lose weight. Eli Lilly (LLY) was one of […]